Please login to the form below

Not currently logged in

Chiesi launches Flogoprofen website

Targets consumers and health professionals in Spain
Chiesi flogoprofen website

Chiesi Spain has unveiled a dedicated website for its anti-inflammatory drug Flogoprofen (etofenamate).

The new website – – is aimed at both consumers and health professionals authorised to prescribe drugs.

In addition to offering readers a better understanding of Flogoprofen and its uses, the site will look into the lesser-known aspects of pain, along with providing exercise videos aimed at showing the public how to prevent and relieve it.
Chiesi Spain said the website content is designed to encourage 'total interactivity' with its users, and will evolve as time goes on and user preferences become clear.

“We are working to give people a website that serves as a comprehensive reference point for queries on topics related to musculoskeletal pain,” said Elizabeth Font, product manager at Chiesi Flogoprofen Spain.

Although still awaiting the bulk of its planned content, the section of the website aimed at health professionals already includes suggestions on how best to promote Flogoprofen to patients, for instance by underlining its popularity, with 25 million units sold over the last 10 years.

The website will feature a blog aimed at amateur sportsmen and women, and the videos can also be seen on YouTube.

Chiesi has been active in Spain since 1995, when it acquired Laboratorios Wassermann. The company has also since acquired Laboratorios Dreiman Chiesi and Advent International, and has more than 200 employees in Spain today.

In addition to Flogoprofen, Chiesi Spain manufactures drugs for the treatment of cardiovascular, neonatal and respiratory conditions.

Article by
Tara Craig

2nd May 2014

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company

WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...

Latest intelligence

When is it time to rebrand?
The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....